抗肥満薬

抗肥満薬の世界市場は2030年までに54億米ドルに到達

2024年に33億米ドルと推定される抗肥満薬の世界市場は、分析期間2024-2030年にCAGR 8.7%で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである処方薬は、CAGR 8.5%を記録し、分析期間終了時には49億米ドルに達すると予想されます。OTC医薬品セグメントの成長率は、分析期間中CAGR 11.0%と推定されます。

米国市場は9億1,330万米ドルと推定、中国はCAGR 7.9％で成長予測

米国の抗肥満薬市場は2024年に9億1,330万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.9%として、2030年までに8億1,220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.9%と7.1%と予測されています。欧州では、ドイツがCAGR約7.0%で成長すると予測されています。

世界の抗肥満薬市場- 主要動向と促進要因のまとめ

抗肥満薬とは何か？

抗肥満薬は、空腹感、満腹感、脂肪吸収に関与する様々な生理学的経路を標的とすることで、個人の減量や減量の維持を助けるように設計された医薬品です。これらの薬は、食欲抑制、満腹感の増加、食事からの脂肪吸収の減少、エネルギー消費の促進など、さまざまなメカニズムで機能します。一般的に処方される抗肥満薬には、腸での脂肪吸収を阻害するオルリスタットや、中枢神経系に作用して食欲を減退させるリラグルチドやフェンテルミン-トピラマートなどの薬剤が含まれます。これらの薬剤は通常、肥満度指数（BMI）が30以上の人、または高血圧、2型糖尿病、脂質異常症など、体重に関連した健康状態にあるBMI27以上の人に処方されます。これらの薬剤の目的は、患者が持続可能な減量を達成し、全体的な健康増進に貢献できるよう支援することです。

抗肥満薬は臨床でどのように使用されていますか？

臨床において、抗肥満薬は、食事療法、運動療法、行動療法などのライフスタイルの改善を含む包括的な体重管理計画の一部です。通常、医師はこれらの薬剤を処方する前に、患者の健康状態、体重履歴、減量目標を評価します。抗肥満薬の有効性と安全性は、定期的なフォローアップ診察によって注意深くモニターされます。患者さんには、薬の効果を最大限に引き出すために、カロリーを抑えた食事を守り、運動量を増やすようアドバイスされることがよくあります。場合によっては、抗肥満薬は肥満手術の補助として、手術のリスクを減らすために術前に、あるいは体重減少を維持するために術後に使用されます。薬物療法と生活習慣への介入を統合することで、長期的な体重管理を達成し、心血管疾患、2型糖尿病、特定のがんなどの肥満に伴う健康リスクを軽減することを目的としています。

抗肥満薬開発における最近の技術革新とは？

抗肥満薬開発の分野では、肥満の根底にある生物学的メカニズムの理解が深まったことにより、大きな進歩が見られました。最近のイノベーションには、セマグルチドのようなGLP-1受容体作動薬の開発が含まれます。セマグルチドは腸内ホルモンであるGLP-1の作用を模倣し、満腹感を高めて食欲を減退させています。セマグルチドは臨床試験で有望な結果を示しており、既存の治療法と比べて有意な体重減少効果が得られています。もう一つのエキサイティングな研究分野は、複数の代謝経路を同時に標的とするデュアルアゴニストの開発です。例えば、TirzepatideはGLP-1とGIPの両方の受容体に作用し、グルコースとエネルギーバランスを調節します。さらに、患者の服薬アドヒアランスと利便性を向上させるため、長時間作用型の注射剤や経口剤を含む新規ドラッグデリバリーシステムが研究されています。また、ゲノミクスと個別化医療の進歩により、遺伝的・代謝的プロファイルに基づいて特定の患者集団をより正確にターゲットとした、よりオーダーメイドの肥満治療への道が開かれつつあります。

抗肥満薬市場の成長を促進する要因とは？

抗肥満薬市場の成長は、いくつかの要因によってもたらされます。座りがちなライフスタイルや不健康な食習慣によって悪化した肥満の世界の有病率の上昇は、効果的な体重管理ソリューションに対する大きな需要を生み出す主要な促進要因です。新規作用機序や革新的デリバリー方法など、医薬品開発における技術的進歩が抗肥満薬の有効性と安全性プロファイルを高め、より多くの医療従事者や患者を惹きつけています。肥満に伴う健康リスクに対する意識の高まりと、実行可能な体重管理の選択肢として薬物療法が受け入れられつつあることも、市場の成長に寄与しています。いくつかの地域における規制当局の承認と有利な償還政策は、これらの薬剤の入手しやすさと手頃な価格を促進しています。さらに、肥満に影響を及ぼす代謝および遺伝的要因に関する研究の拡大が、より的を絞った個別化治療の開発につながり、市場をさらに押し上げています。これらの要因を総合すると、肥満の世界的流行に対処する上で重要な役割を果たす抗肥満薬市場のダイナミックな拡大が強調されます。

セグメント

タイプ（処方薬、OTC薬）

調査対象企業の例（注目23社）

• Eisai Co. Ltd.（Japan）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GlaxoSmithKline Plc
• Novo Nordisk A/S（Denmark）
• Rhythm Pharmaceuticals（US）
• VIVUS Inc.（US）

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Anti-Obesity Drugs Market to Reach US$5.4 Billion by 2030

The global market for Anti-Obesity Drugs estimated at US$3.3 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the OTC Drugs segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$913.3 Million While China is Forecast to Grow at 7.9% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$913.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Anti-Obesity Drugs Market - Key Trends and Drivers Summarized

What Are Anti-Obesity Drugs and How Do They Work?

Anti-obesity drugs are medications designed to help individuals lose weight and maintain weight loss by targeting various physiological pathways involved in hunger, satiety, and fat absorption. These drugs function through different mechanisms such as appetite suppression, increasing feelings of fullness, reducing fat absorption from the diet, and enhancing energy expenditure. Commonly prescribed anti-obesity drugs include orlistat, which inhibits fat absorption in the intestines, and medications like liraglutide and phentermine-topiramate, which act on the central nervous system to reduce appetite. These drugs are typically prescribed for individuals with a Body Mass Index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who have weight-related health conditions such as hypertension, type 2 diabetes, or dyslipidemia. The goal of these medications is to assist patients in achieving a sustainable weight loss that contributes to overall health improvement.

How Are Anti-Obesity Drugs Utilized in Clinical Practice?

In clinical practice, anti-obesity drugs are part of a comprehensive weight management plan that includes lifestyle modifications such as diet, exercise, and behavioral therapy. Physicians typically evaluate a patient's health status, weight history, and weight-loss goals before prescribing these medications. The effectiveness and safety of anti-obesity drugs are closely monitored through regular follow-up appointments. Patients are often advised to adhere to a reduced-calorie diet and increase physical activity to maximize the benefits of the medication. In some cases, anti-obesity drugs are used as an adjunct to bariatric surgery, either preoperatively to reduce surgical risks or postoperatively to maintain weight loss. The integration of pharmacotherapy with lifestyle interventions aims to achieve long-term weight management and mitigate the health risks associated with obesity, such as cardiovascular disease, type 2 diabetes, and certain cancers.

What Are the Recent Innovations in Anti-Obesity Drug Development?

The field of anti-obesity drug development has seen significant advancements driven by a deeper understanding of the biological mechanisms underlying obesity. Recent innovations include the development of GLP-1 receptor agonists like semaglutide, which mimic the effects of the gut hormone GLP-1 to enhance satiety and reduce appetite. Semaglutide has shown promising results in clinical trials, with significant weight loss outcomes compared to existing therapies. Another exciting area of research is the development of dual agonists that target multiple metabolic pathways simultaneously, such as tirzepatide, which acts on both GLP-1 and GIP receptors to regulate glucose and energy balance. Additionally, novel drug delivery systems, including long-acting injectables and oral formulations, are being explored to improve patient adherence and convenience. Advances in genomics and personalized medicine are also paving the way for more tailored obesity treatments, allowing for more precise targeting of specific patient populations based on genetic and metabolic profiles.

What Factors Are Driving the Growth in the Anti-Obesity Drugs Market?

The growth in the anti-obesity drugs market is driven by several factors. The rising prevalence of obesity worldwide, exacerbated by sedentary lifestyles and unhealthy dietary habits, is a primary driver, creating a substantial demand for effective weight management solutions. Technological advancements in drug development, including novel mechanisms of action and innovative delivery methods, are enhancing the efficacy and safety profiles of anti-obesity medications, attracting more healthcare providers and patients. Increased awareness of the health risks associated with obesity, coupled with growing acceptance of pharmacotherapy as a viable weight management option, is also contributing to market growth. Regulatory approvals and favorable reimbursement policies in several regions are facilitating the accessibility and affordability of these drugs. Furthermore, the expanding research on the metabolic and genetic factors influencing obesity is leading to the development of more targeted and personalized treatments, further boosting the market. Collectively, these factors underscore the dynamic expansion of the anti-obesity drugs market, reflecting its critical role in addressing the global obesity epidemic.

SCOPE OF STUDY:

The report analyzes the Anti-Obesity Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prescription Drugs, OTC Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 23 Featured) -

• Eisai Co. Ltd. (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline Plc
• Novo Nordisk A/S (Denmark)
• Rhythm Pharmaceuticals (US)
• VIVUS Inc. (US)

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Anti-Obesity Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Obesity Throws the Spotlight on Anti-Obesity Drugs
  • Advances in Pharmacotherapy Propel Growth in Anti-Obesity Drugs Market
  • Increasing Awareness of Obesity-Related Health Risks Expands Addressable Market Opportunity
  • Development of Novel Drug Formulations Strengthens Business Case for Anti-Obesity Treatments
  • Growing Adoption of Combination Therapies Generates Demand for Comprehensive Solutions
  • Technological Innovations in Drug Delivery Systems Drives Adoption of Anti-Obesity Drugs
  • Expansion of Weight Management Programs Sustains Growth in Anti-Obesity Drugs Market
  • Increasing Focus on Personalized Medicine Accelerates Market Demand
  • Regulatory Approvals for New Drugs Spurs Market Growth
  • Integration with Digital Health Platforms Propels Market Growth for Anti-Obesity Treatments
  • Growing Need for Non-Invasive Treatments Drives Adoption of Anti-Obesity Drugs
  • Expansion of Lifestyle-Related Health Initiatives Generates Demand for Effective Treatments
  • Development of Targeted Therapies for Specific Patient Populations Expands Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anti-Obesity Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 8: USA Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 9: USA 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• CANADA
  • TABLE 10: Canada Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 11: Canada 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• JAPAN
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 12: Japan Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 13: Japan 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• CHINA
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 14: China Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 15: China 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• EUROPE
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 16: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 17: Europe 6-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 18: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 19: Europe 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• FRANCE
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 20: France Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: France 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• GERMANY
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 22: Germany Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Germany 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• ITALY
  • TABLE 24: Italy Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Italy 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• UNITED KINGDOM
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 26: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: UK 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Rest of Europe 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• ASIA-PACIFIC
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Asia-Pacific 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Rest of World 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030

IV. COMPETITION